loader2
Login Open ICICI 3-in-1 Account

Glaxosmithkline Pharmaceuticals Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
GlaxoSmithKline Pharmaceuticals Ltd. 06 Nov 2025 17:08 PM

Q2FY26 Quarterly Result Announced for GlaxoSmithKline Pharmaceuticals Ltd.

Pharmaceuticals company GlaxoSmithKline Pharmaceuticals announced Q2FY26 results

  • Revenue from Operations was Rs 974 crore for Q2FY26.
  • EBIDTA margins for Q2FY26 stood at 34.4%, growth 250 bps.
  • Profit After Tax (PAT) was Rs 255 crore for Q2FY26.

Bhushan Akshikar, Managing Director, GSK India, said: “Within two months of launch, our Oncology portfolio is impacting patients by addressing a critical unmet need in gynaecological cancers in India. Together, these assets represent meaningful progress in women’s cancer care. Moving ahead, we remain focused on ensuring that cutting-edge innovative treatments are both available and accessible to those who need them the most, supported by our comprehensive patient support and financing initiatives.”

Result PDF

Pharmaceuticals company GlaxoSmithKline Pharmaceuticals announced Q1FY26 results

  • Revenue from Operations stood at Rs 805 crore.
  • Profit After Tax (PAT) of Rs 205 crore.

Bhushan Akshikar, Managing Director, GlaxoSmithKline Pharmaceuticals, said: “GSK continues to invest in its innovative portfolio and is on track to launch the much-awaited oncology assets, Jemperli and Zejula. By launching these assets in India, GSK is addressing a critical unmet need amid a rising cancer burden and limited access to advanced therapies.”

Jemperli (dostarlimab) is an immuno-oncology treatment for second-line dMMR endometrial cancer and Zejula (niraparib), is a PARP inhibitor indicated for advanced and recurrent ovarian cancer.

Result PDF

Pharmaceuticals company GlaxoSmithKline Pharmaceuticals announced Q4FY25 & FY25 results

Q4FY25 Financial Highlights:

  • The company reported a revenue of Rs 966 crore, a like-to-like growth of 6%.
  • Profit After Tax for the quarter stood at Rs 260 crore.

FY25 Financial Highlights:

  • The company reported full year revenue of Rs 3,723 crore, a growth of 9%.
  • Profit After Tax before exceptional items increased by 32% to Rs 915 crore
  • EBITDA margins increased by 500 basis points (bps) to 31.4%.

Bhushan Akshikar, Managing Director, GlaxoSmithKline Pharmaceuticals, said, “Our diversified portfolio of General Medicines, Specialty, and Vaccines has shown improved growth due to sustained innovation, enhanced Healthcare Professionals (HCP) engagement and rapid digital acceleration. This has enhanced reach, expanded coverage, and provided a seamless omnichannel experience for our customeRs Our key brands, including Augmentin, Calpol, Ceftum, T-Bact, and Trelegy, have played a significant role in driving growth throughout the year. Shingrix is experiencing increased adoption, driven by heightened awareness and our efforts to develop the adult vaccination ecosystem in the country.”

“We remain committed to delivering sustained above-market growth and strong shareholder returns. In FY2025-26, we will continue to focus on our innovative portfolio through the launch of our oncology assets,” he added.

Result PDF

Pharmaceuticals company GlaxoSmithKline Pharmaceuticals announced Q3FY25 results

  • Revenue Growth: The company reported an 18% increase in revenue from operations for Q3 of the financial year 2024-25, achieving total revenue of Rs 946 crore.
  • Profit Performance: GlaxoSmithKline Pharmaceuticals Limited recorded a Profit After Tax (PAT) of Rs 229 crore for the quarter.

Bhushan Akshikar, Managing Director, GlaxoSmithKline Pharmaceuticals, stated: "Our strong third-quarter results reflect our unwavering commitment to deliver innovative healthcare solutions to patients across India. By focusing on core brands and accelerating digital transformation through innovative go-to-market strategies, we continue to strengthen our market presence while ensuring broader access to our medicines and vaccines."

Result PDF

Pharmaceuticals company GlaxoSmithKline Pharmaceuticals announced H1FY25 & Q2FY25 results

Q2FY25 Financial Highlights:

  • Revenue from operations for the quarter grew by 5% to cross Rs 1,000 crore.
  • Profit After Tax (PAT) for the quarter Rs 249 crore grew by 15%.

H1FY25 Financial Highlights:

  • The company delivered Rs 1,811 crore Revenue from Operations recording a growth of 7%.
  • Profit before exceptional items and tax for the half year at Rs 583 crore improved by 27% with EBITDA margins at 30%.
  • The Board of Directors at it’s meeting held on 29th October 2024 declared a special interim dividend of Rs 12 per equity share of face value of Rs 10 each.

Bhushan Akshikar, Managing Director, GlaxoSmithKline Pharmaceuticals, said: “As we mark our centenary year in India, we are happy to announce a special interim dividend to our shareholders.

Our performance reflects our commitment to sustainable growth and innovation. Furthermore, our shingles diseases awareness campaign featuring Mr. Amitabh Bachchan has significantly elevated the discussion around Shingles prevention, reinforcing our focus in preventive healthcare in India.

Result PDF

Pharmaceuticals company GlaxoSmithKline Pharmaceuticals announced Q1FY25 results:

Financial Highlights: 

  • GlaxoSmithKline Pharmaceuticals Limited (GSK) today announced its financial results for quarter ended June 30, 2024. Revenue from operations for the quarter grew by 10% at Rs 811 crore. Profit After Tax (PAT) for the quarter at Rs 182 crore.
  • The company continued to deliver a strong growth of 10% with key brands such as Calpol, Augmentin, T-Bact and gaining market share. In addition, the Respiratory portfolio comprising Nucala and Trelegy delivered a growth of 57% by further improving access to more patients.

Commenting on the results, Bhushan Akshikar, Managing Director, GlaxoSmithKline Pharmaceuticals, said “We continue our growth momentum across General Medicines and Vaccines portfolios while maintaining profitability. As we celebrate hundred years of our operations in India, we remain committed to pursuing new growth opportunities, enhancing our leadership in key therapeutic areas and advancing our innovative omnichannel strategies to further enhance customer experience.”

Result PDF

Pharmaceuticals company GlaxoSmithKline Pharmaceuticals announced Q4FY24 & FY24 results:

Q4FY24 Financial Highlights:

  • Revenue for the quarter came in at Rs 911 crore recorded a growth of 16%.
  • Profit before exceptional items and tax for the quarter at Rs 266 crore recorded a growth of 51% with EBITDA margins at 28%.

FY24 Financial Highlights:

  • The full year reported revenue was at Rs 3,407 crore, a growth of 6%, demonstrating positive growth driven by a strong volume recovery thereby offsetting NLEM (National List of Essential Medicines) impact.
  • Profit before exceptional items and tax for the year at Rs 953 crore recorded a growth of 14% with EBITDA at 26.4% up by 150 bps.

Commenting on the results for Q4 and FY 2023-24, Bhushan Akshikar, Managing Director, GlaxoSmithKline Pharmaceuticals Limited, said, “For Q4, we delivered a strong double-digit growth and a robust performance across our General Medicines, Specialty and Vaccines portfolio. Our General Medicines portfolio recorded strong double-digit growth of 12% for the quarter, driven by key focus brands Augmentin, Ceftum and Calpol. Despite the NLEM impact in previous quarters, all promoted brands outpaced their respective categories in growth and gained market share.

Specialty portfolio led by Nucala and Trelegy has accelerated the momentum with highest patient recruitment in Q4.

For the vaccines business, over the last two quarters, we have seen a steady upswing in both adult and paediatric segments. This business delivered a Q4 growth of 35%. We continue to build on the momentum generated with the launch of Shingrix (Zoster Vaccine Recombinant, Adjuvanted) as we drive expansion of the Adult Immunisation category in India with innovative go-to-market (GTM) strategies."

Result PDF

Pharmaceutical company Pharmaceutical company GlaxoSmithKline Pharmaceuticals announced Q3FY24 results: 

Revenue and Profitability:

  • Revenue from operations at Rs 805 crore for Q3FY24.
  • The company announced a Profit before exceptional items and tax at Rs 228 crore.
  • EBITDA margins were reported at 27%.

Market Performance:

  • GSK experienced a 1% value growth in a flat general medicine market during the quarter, notwithstanding the impact of the National List of Essential Medicines (NLEM).
  • Augmentin continued to lead, improving its market share and retaining the number 1 rank within the Indian Pharmaceutical Market (IPM).

Product Portfolio and Strategic Developments:

  • The Vaccines market and portfolio of GSK continued to exhibit sequential growth.
  • The company is focusing on newer capabilities to improve reach and access for its innovative portfolio, which includes products like Shingrix, Nucala, and Trelegy.

Commenting on the results, Bhushan Akshikar, Managing Director, GlaxoSmithKline Pharmaceuticals, said, "We remain committed to new category development in areas like Adult Immunization with products like Shingrix to make a positive impact on the lives of patients in India. We will continue to drive operational efficiency and explore new innovative solutions including Omnichannel Strategy to expand reach and coverage to the target segments."

Result PDF

GlaxoSmithKline Pharmaceuticals announced Q2FY24 & H1FY24 results:

  • Q2FY24:
    • Revenue from operations: Rs 953 crore, with a 5% YoY growth.
    • PBT: Rs 297 crore, showing a solid 13% YoY increase.
    • EBITDA margins: 30.1%.
  • H1FY24:
    • Revenue from operations: Rs 1,691 crore, recording a 3% YoY growth.
    • PBT: Rs 458 crore, improved by 9% YoY.
    • EBITDA margins: 25.3%.

Commenting on the results, Bhushan Akshikar, Managing Director, GlaxoSmithKline Pharmaceuticals, said, "Our Q2 performance reflects an overall recovery with market share gains in several key promoted brands across all business units. We held leadership positions for our key brands in relevant therapy areas such as anti-infectives and dermatology.

Our focus in the coming quarters will remain on strong volume-led performance in General Medicines and Pediatric vaccines. We will also explore innovative solutions using Omnichannel strategy to expand our reach and coverage to our target segments. We continue to drive the expansion of the adult immunisation category with Shingrix (Zoster Vaccine Recombinant, Adjuvanted).”

 

 

Result PDF

GlaxoSmithKline Pharmaceuticals announced Q1FY24 results:

  • Revenue from operations for the quarter grew by ~ 1% at Rs 738 crore.
  • The company maintained its gross margins despite the NLEM impact.
  • EBITDA margins declined ~ 1% on account of new product launch investments led by Shingrix.
  • Profit After Tax (PAT) for Q1FY24 at Rs 131 crore grew by ~ 13%.
  • General medicines delivers 4% revenue growth despite NLEM impact along with a sequential recovery in the vaccines business.
  • During Q1FY24, the company delivered a robust volume growth of 8% for its key promoted portfolio with market share gains.

Bhushan Akshikar, Managing Director, GSK Pharmaceuticals, said, "Despite the strong external headwinds, GSK remains focused on delivering best-in-class competitive performance and driving operational efficiencies. We remain committed to exploring new growth opportunities and improving our leadership in key therapy areas.”

 

 

Result PDF

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Play Store App Store
market app